KIRA-7|cas:1937235-76-1|西域试剂

KIRA-7,98.33%

产品编号：Bellancom-124646| CAS NO：1937235-76-1| 分子式：C₂₇H₂₃FN₆O| 分子量：466.51

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-124646		￥5800.00	杭州北京（现货）
Bellancom-124646		￥9800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

KIRA-7

产品介绍

KIRA-7 是一种咪唑并吡嗪化合物，可与 IRE1α 激酶结合 (IC₅₀ 为 110 nM) 以变构方式抑制其 RNase 活性。KIRA-7 具有抗纤维化作用。

生物活性

KIRA-7, an imidazopyrazine compound, binds the IRE1α kinase (IC₅₀ of 110 nM) to allosterically inhibit its RNase activity. KIRA-7 has an anti-fibrotic effect.

体外研究

KIRA-7 can inhibit XBP1 splicing in the alveolar epithelial cell line MLE12.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

KIRA-7 (5 mg/kg; intraperitoneal injection; daily for 14 days; C57BL6 mice) treatment results in decreased spliced XBP1 and ATF4, compared to bleomycin exposed mice treated with vehicle. Likewise, mRNA levels of BiP and CHOP are significantly elevated after Bleomycin exposure, and treatment of Bleomycin-exposed mice with KIRA-7 decreased these levels. mRNA levels of collagen 1A1 and fibronectin are both significantly decreased by KIRA-7 treatment.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL6 mice (12 weeks of age) with Bleomycin (1.5 units/kg)
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; daily; for 14 days
Result:	Resulted in decreased spliced XBP1 and ATF4. Likewise, mRNA levels of BiP and CHOP were significantly decreased.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL6 mice (12 weeks of age) with Bleomycin (1.5 units/kg)
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; daily; for 14 days
Result:	Resulted in decreased spliced XBP1 and ATF4. Likewise, mRNA levels of BiP and CHOP were significantly decreased.